988 related articles for article (PubMed ID: 31452208)
21. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
22. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
23. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
24. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
[TBL] [Abstract][Full Text] [Related]
25. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
[TBL] [Abstract][Full Text] [Related]
27. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
28. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
29. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
[TBL] [Abstract][Full Text] [Related]
30. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Ielpo B; Caruso R; Duran H; Diaz E; Fabra I; Malavé L; Ferri V; Alvarez R; Cubillo A; Plaza C; Lazzaro S; Kalivaci D; Quijano Y; Vicente E
Surg Oncol; 2017 Dec; 26(4):402-410. PubMed ID: 29113659
[TBL] [Abstract][Full Text] [Related]
33. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
[TBL] [Abstract][Full Text] [Related]
34. The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database.
Hu H; Xu Y; Zhang Q; Gao Y; Wu Z
Expert Rev Anticancer Ther; 2024 Jun; 24(6):467-476. PubMed ID: 38656796
[TBL] [Abstract][Full Text] [Related]
35. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
36. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
37. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
38. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
39. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
40. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
